A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2016 Primary end points has been modified.
- 02 May 2012 Actual patient number is 55 according to ClinicalTrials.gov.